Results from the first five Phase III studies to evaluate Roche's weekly type 2 diabetes drug taspoglutide have shown good results in reducing blood glucose compared with other diabetes treatment options.
Results from the first five Phase III clinical trials have shown that taspoglutide, the first weekly human GLP-1 analogue in late-stage development for type 2 diabetes, has met the primary endpoints of reduction in blood glucose levels.
Roche global head of product development Hal Barron said that taspoglutide has the potential to become an important therapy.
"These Phase III studies have shown that treatment with once-weekly taspoglutide leads to significantly improved blood glucose control, consistent weight loss, a minimal risk of hypoglycaemia and a manageable safety profile," Barron said.
Taspoglutide is similar to the naturally occurring human hormone GLP-1, which plays a key role in blood glucose metabolism through a range of mechanisms including improvement of insulin secretion, suppression of abnormal glucose production by the liver, slowing food absorption through the gut and suppressing appetite in animal studies.
The Phase III clinical trials programme, called T-emerge, includes placebo-controlled and active-comparator controlled studies with current standards of care in patients treated with metformin or other therapies as well as evaluating the effect of this innovative option in patients who are not controlled with diet and exercise alone.